1. Khan, S. A., Tavolari, S. & Brandi, G. Cholangiocarcinoma: Epidemiology and risk factors. Liver Int 39 Suppl 1, 19-31 (2019).
2. Razumilava, N. & Gores, G. J. Cholangiocarcinoma. The Lancet 383, 2168-2179 (2014).
3. Brindley, P. J. et al. Cholangiocarcinoma. Nat Rev Dis Primers 7, 65 (2021).
4. Bekaii-Saab, T. S., Bridgewater, J. & Normanno, N. Practical considerations in screening for genetic alterations in cholangiocarcinoma. Ann Oncol 32, 1111-1126 (2021).
5. Banales, J. M. et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 17, 557-588 (2020).
6. Liau, J. Y. et al. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features. Mod Pathol 27, 1163-1173 (2014).
7. Kendall, T. et al. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int 39 Suppl 1, 7-18 (2019).
8. Hayashi, A. et al. Distinct Clinicopathologic and Genetic Features of 2 Histologic Subtypes of Intrahepatic Cholangiocarcinoma. Am J Surg Pathol 40, 1021-1030 (2016).
9. Akita, M. et al. Histological and molecular characterization of intrahepatic bile duct cancers suggests an expanded definition of perihilar cholangiocarcinoma. HPB (Oxford) 21, 226-234 (2019).
10. Akita, M. et al. An immunostaining panel of C-reactive protein, N-cadherin, and S100 calcium binding protein P is useful for intrahepatic cholangiocarcinoma subtyping. Hum Pathol 109, 45-52 (2021).
11. Akita, M. et al. Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas. Mod Pathol 30, 986-997 (2017).
12. Broutier, L. et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat Med 23, 1424-1435 (2017).
13. Saito, Y. et al. Induction of differentiation of intrahepatic cholangiocarcinoma cells to functional hepatocytes using an organoid culture system. Sci Rep 8, 2821 (2018).
14. Wang, Z. et al. Conversion Therapy of Intrahepatic Cholangiocarcinoma Is Associated with Improved Prognosis and Verified by a Case of Patient-Derived Organoid. Cancers (Basel) 13 (2021).
15. Li, L. et al. Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity. JCI Insight 4 (2019).
16. Maier, C. F. et al. Patient-Derived Organoids of Cholangiocarcinoma. Int J Mol Sci 22 (2021).
17. Saito, Y. et al. Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma. Cell Rep 27, 1265-1276.e1264 (2019).
18. Nuciforo, S. et al. Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies. Cell Rep 24, 1363-1376 (2018).
19. Bang, Y.-J. et al. Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies. Journal of Clinical Oncology 37, 4079-4079 (2019).
20. Clements, O., Eliahoo, J., Kim, J. U., Taylor-Robinson, S. D. & Khan, S. A. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis. Journal of Hepatology 72, 95-103 (2020).
21. Montal, R. et al. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. J Hepatol 73, 315-327 (2020).
22. Tsai, J. H. et al. S100P immunostaining identifies a subset of peripheral-type intrahepatic cholangiocarcinomas with morphological and molecular features similar to those of perihilar and extrahepatic cholangiocarcinomas. Histopathology 61, 1106-1116 (2012).
23. Jusakul, A. et al. Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. Cancer Discov 7, 1116-1135 (2017).
24. Wardell, C. P. et al. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. J Hepatol 68, 959-969 (2018).
25. Daneshmand, S. et al. PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations. Journal of Clinical Oncology 38, TPS5095-TPS5095 (2020).
26. Borad, M. J. et al. A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) cholangiocarcinoma (CCA) harboring fibroblast growth factor receptor 2 (FGFR2) gene rearrangements (FOENIX-CCA3). Journal of Clinical Oncology 38, TPS600-TPS600 (2020).
27. Bekaii-Saab, T. S. et al. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. Future Oncol 16, 2385-2399 (2020).
28. Chen, X. X. et al. BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways. Cell Death Dis 9, 1036 (2018).
29. Artegiani, B. et al. Probing the Tumor Suppressor Function of BAP1 in CRISPR-Engineered Human Liver Organoids. Cell Stem Cell 24, 927-943 e926 (2019).
30. Vendrell, J. A. et al. ZNF217 is a marker of poor prognosis in breast cancer that drives epithelial-mesenchymal transition and invasion. Cancer Res 72, 3593-3606 (2012).
31. Littlepage, L. E. et al. The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. Cancer Discov 2, 638-651 (2012).
32. Guo, L., Chen, J., Liu, D. & Liu, L. OIP5-AS1/miR-137/ZNF217 Axis Promotes Malignant Behaviors in Epithelial Ovarian Cancer. Cancer Manag Res 12, 6707-6717 (2020).
33. Bellanger, A. et al. The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone. J Pathol 242, 73-89 (2017).
34. Huang, G. et al. ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction. Hum Mol Genet 14, 3219-3225 (2005).
35. Thollet, A. et al. ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells. Mol Cancer 9, 291 (2010).
36. Maru, Y. et al. Establishment and characterization of patient-derived organoids from a young patient with cervical clear cell carcinoma. Cancer Science 110, 2992-3005 (2019).
37. Lee, H. S. et al. Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer. EBioMedicine 65, 103218 (2021).
38. Broutier, L. et al. Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation. Nat Protoc 11, 1724-1743 (2016).
39. Saito, Y. Establishment of an organoid bank of biliary tract and pancreatic cancers and its application for personalized therapy and future treatment. J Gastroenterol Hepatol 34, 1906-1910 (2019).
40. Danecek, P. et al. Twelve years of SAMtools and BCFtools. Gigascience 10 (2021).
41. McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biology 17, 122 (2016).
42. Mayakonda, A., Lin, D. C., Assenov, Y., Plass, C. & Koeffler, H. P. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res 28, 1747-1756 (2018).
43. Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. 2011 17, 3 (2011).
44. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15-21 (2013).
45. Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).
46. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15, 550 (2014).
47. Chen, E. Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 14, 128 (2013).
48. Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res 44, W90-97 (2016).